249 results on '"RICHTIG, Erika"'
Search Results
2. Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
3. ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study
4. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
5. Coping and vegetative reactivity in uveal melanoma
6. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
7. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
8. Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
9. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
10. Awareness of predatory journals and open access among medical oncologists: results of an online survey
11. The therapeutic landscape of advanced melanoma
12. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
13. ASCO Congress 2018: melanoma treatment
14. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
15. Verwendung und Nutzen des Internets als Informationsquelle für Erkrankungen und Therapien in der Dermatologie: Usage and benefit of the Internet as a source of information on disease and therapy in dermatology.
16. Usage and benefit of the Internet as a source of information on disease and therapy in dermatology.
17. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401
18. Interplay between pregnancy associated melanoma cells and placental tissue
19. Predatory journals: Perception, impact and use of Beall's list by the scientific community–A bibliometric big data study.
20. Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types.
21. Karnofsky Performance Status and Lactate Dehydrogenase Predict the Benefit of Palliative Whole-Brain Irradiation in Patients With Advanced Intra- and Extracranial Metastases From Malignant Melanoma
22. Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFᵛ⁶⁰⁰-mutant melanoma : Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGᴹᴱᴸᴬᴺᴼᴹᴬ
23. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
24. A Unifying Concept of Uveal Pigment Cell Distribution and Dissemination Based on an Animal Model: Insights into Ocular Melanogenesis
25. Reflectance Confocal Microscopy—State-of-Art and Research Overview
26. Suction Drain Volume following Axillary Lymph Node Dissection for Melanoma—When to Remove Drains? A Retrospective Cohort Study.
27. Spatiotemporal Analysis of B Cell- and Antibody Secreting Cell-Subsets in Human Melanoma Reveals Metastasis-, Tumor Stage-, and Age-Associated Dynamics
28. The importance of the given history in the differential diagnosis of blue nodules
29. New insights into oculodermal nevogenesis and proposal for a new iris nevus classification
30. Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma.
31. Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib
32. New ways to strengthen old risk factors.
33. Ist Konfokale Laserscanmikroskopie eine nützliche Ergänzung in der Diagnostik regressiver Läsionen?: FV2–2
34. Neurofibroma of the Tibial Nerve Mimicking Popliteal Lymph Node Metastasis in Malignant Melanoma
35. Knowledge and Perception of Melanocytic Nevi and Sunburn in Young Children
36. Reflectance Confocal Microscopy—State-of-Art and Research Overview
37. Diagnostic image analysis of malignant melanoma in in vivo confocal laser-scanning microscopy: a preliminary study
38. Repigmentation after Surgery of Melanoma in a Burn Scar: Dermoscopy as Aid for the Management Decision
39. Natural history of invasive cutaneous melanoma in Styria, Austria 2001–2003
40. Klinisch-epidemiologische Daten des invasiven kutanen Melanoms in der Steiermark, Österreich 2001–2003
41. Dermoscopy Patterns of Halo Nevi
42. Malignant Melanoma in Marathon Runners
43. Sensitivity and specificity of confocal laser-scanning microscopy for in vivo diagnosis of malignant skin tumors
44. Speckled Posttraumatic Hyperpigmentation by Foreign Bodies on the Lower Legs After Welding
45. Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial Comparing Adjuvant Interferon Alfa and Isotretinoin With Interferon Alfa Alone in Stage IIA and IIB Melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group
46. Digital image enhancement for in vivo laser scanning microscopy
47. Diagnostic Applicability of In Vivo Confocal Laser Scanning Microscopy in Melanocytic Skin Tumors
48. Adjuvante Anti‐PD‐1‐Antikörpertherapie bei Stadium‐III/IV‐Melanom: Anwendungsdaten aus der klinischen Routine und gesundheitsökonomische Aspekte.
49. Adjuvant anti‐PD‐1 antibody treatment in stage III/IV melanoma: real‐world experience and health economic considerations.
50. Prevalence of nevi, atypical nevi, and lentigines in relation to tobacco smoking.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.